Navigating aggressive hematologic malignancies, complex solid tumor resections, acute post-chemotherapy pancytopenia, or the vulnerable engraftment phase following allogeneic or autologous hematopoietic stem cell transplantation (HSCT) overseas is an intensely demanding clinical and logistical journey. Every year, thousands of international cancer patients, expatriate corporate personnel, overseas research scholars, and Non-Resident Indians (NRIs) travel to India’s world-renowned…